Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

• Bladder
• Breast
• Colon
• Gastrointestinal
• Hematology
• Leukemia
• Lung
• Lymphoma
• Melanoma
• Ovarian
• Pancreatic
• Prostate
• Renal
• Solid Tumors

 

Bladder

• IMMU-132 for Metastatic Urothelial Cancer

  A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)
  

  ---

Breast

• Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

  Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
  

  ---

• Enobosarm Vs Active Control in patients with AR+/ER+/Her2- Metastatic Breast Cancer

  A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining greater than or equal to 40% Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 inhibitor
  

  ---

• Trilaciclib + Sacituzumab Govitecan-hziy in Triple Negative Breast Cancer Patients

  A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
  

  ---

• Study of Trilaciclib prior to Sacituzumab in Patients with Triple Negative Breast Cancer

  A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
  

  ---

• Adjuvant Giredestrant compared w/Physician’s choice in patients with ER+, HER2- early breast cancer

  A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
  

  ---

• A Study of treatments in Her2+ first line metastatic breast cancer

  A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer
  

  ---

• A Phase 3 study of LY3484356 vs Investigator’s choice of endocrine therapy in Breast Cancer

  A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator’s Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy
  

  ---

• Phase 1a/1b Study of LY3484356 in Metastatic Breast Cancer Patient

  A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
  

  ---

Colon

• Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

  Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
  

  ---

• Tucatini with Traztuzumab and mFOLFOX6 vs mFOLFOX6 w/or w/o Cetuximab or Bevacizumab for colorectal

  An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer
  

  ---

• Phase 3 study of MK4280A vs SOC in colorectal cancer

  A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PDL1 positive Colorectal Cancer
  

  ---

• A Phase 3 study of MRTX849 + Cetuximab vs. Chemotherapy in Colorectal Cancer

  A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
  

  ---

• Phase 3b for MSI-H or MMR Colorectal Cancer Patients

  A Phase 3b Randomized Clinical Trial of Nivolumab Alone, or in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
  

  ---

Gastrointestinal

• Study of Carbo/Paclitaxel + INCMGA00012/Placebo in Squamous Cell Carcinoma of the Anal Canal

  A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy
  

  ---

• Phase 3 Study of INCMGA00012 in Anal Cancer

  A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy
  

  ---

Hematology

• A Phase 2 study of Selinexor vs Physician’s choice in patients with Myelofibrosis

  A PHASE 2, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIANíS CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS
  

  ---

• Phase 3 Study of Navitoclax in Myelofibrosis

  A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis
  

  ---

Leukemia

• Phase IIIb study of Asciminib in patients with CML

  An open label, multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation
  

  ---

• Phase 3 study of LOXO-305 vs. Investigator’s choice in BTK Inhibitor pretreated CLL/SLL

  A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  

  ---

• A Phase 3b Study of asciminib chronic myeloid leukemia

  An open label, multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation
  

  ---

• Phase 3 Study of LOXO-305 in CLL/SLL Patients

  A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  

  ---

• Phase III of Obinutuzumab and Venetoclax in Untreated CLL without 17p deletion or Tp53 mutation

  A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION
  

  ---

Lung

• Study of VS-6766 in Recurrent KRAS-Mutant and BRAF Mutant NSCLC

  A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)
  

  ---

• Screening Study to determine biomarker status for patients with malignant tumors

  Master Screening Study to determine biomarker status and potential trial eligibility for patients with malignant tumors
  

  ---

• VS-6766 with Sotorasib in patients with NSCLC

  A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer
  

  ---

• A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies

  A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
  

  ---

• MK-7684A + Etoposide and Platinum for 1st line treatment of Small Cell Lung Cancer

  A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer
  

  ---

• Study of Mk-7684A + Etoposide/Platinum vs Atezolizumab + Etoposide/Platinium in SCLC

  A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer
  

  ---

• Phase III study of osimertinib as monotherapy or in combination w/chemo vs SOC patients w/NSCLC

  A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
  

  ---

• Phase 2 study of Brentuximab Vedotin with Pembrolizumab in subjects with metastatic solid tumors

  A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
  

  ---

• Phase 2 Study of RMC-4630 and Sotorasib for NSCLC patients with KRAS G12C mutation

  A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies
  

  ---

• Phase 3 Study of Selpercatinib in Participants with Stage IB-IIIA RET fusion-Positive NSCLC

  A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC
  

  ---

• A Phase 3 study of Adjuvant Selpercatinib in lung cancer

  A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC
  

  ---

• Phase 3 Study of MRTX849 in Lung Cancer

  A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
  

  ---

• Phase 3 Study of Amivantamab in Lung Cancer

  A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  

  ---

Lymphoma

• Stage 3 study of Tazemetostat/placebo + Lenalidomide and Rituximab in Patients with FL

  A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker adaptive study of Tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory Follicular Lymphoma (EZH-302)
  

  ---

• Loncastuximab tesirine with rituximab in patients with DLBCL

  A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203)
  

  ---

• Zanubrutinib in Patients w/previously treated B-Cell Lymphoma

  A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib 
  

  ---

• Phase 3 study of LOXO-305 vs. Investigator’s choice in BTK Inhibitor pretreated CLL/SLL

  A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  

  ---

• Phase 3 study of tafasitamab plus lenalidomide with R-CHOP vs R-CHOP in DLBCL

  A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma
  

  ---

• Phase 3 Study of Acalabrutinib in Untreated Diffuse Large B-Cell Lymphoma

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
  

  ---

• Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

  A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above
  

  ---

Melanoma

• A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies

  A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
  

  ---

• Phase 2 study of Brentuximab Vedotin with Pembrolizumab in subjects with metastatic solid tumors

  A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment
  

  ---

Ovarian

• Study of Upifitamab rilsodotin + Carboplatin in patients with high grade serous ovarian cancer

  An Open-label, Multicenter, Dose Escalation and Expansion Study of upifitamab rilsodotin in combination with carboplatin In Participants with High-grade Serous Ovarian Cancer: A modular study related to upgrade Umbrella Master study
  

  ---

• Upifitamab Rilsodotin in Combination with Carboplatin in Participants with High-Grade Serous Ovarian

  An Open-Label, Multicenter, Dose Escalation and Expansion Study of Upifitamab Rilsodotin in Combination with Carboplatin in Participants with High-Grade Serous Ovarian Cancer: A Modular Study related to Upgrade Umbrella Master Study
  

  ---

• Phase 2 Study ofVS-6766 +/- Defactinib in Ovarian Cancer

  A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer
  

  ---

Pancreatic

• NIS793/Placebo + Gemcitabine and Nab-paclitaxel for 1st line treatment in pancreatic cancer

  A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma
  

  ---

Prostate

• Study of Abemaciclib + Abiraterone and Prednisone in Metastatic Prostate Cancer

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer (I3Y-MC-JPEG)
  

  ---

• Phase III study comparing [177Lu]Lu-PSMA-617 vs. standard of care patients with prostate cancer

  An international Prospective Open-label, Randomized, Phase III Study comparing [177Lu]Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer 
  

  ---

• A Phase 3 study Abiraterone + Capivasertib/Placebo in Prostate Cancer

  A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency
  

  ---

• A Phase 3 study of Cabozantinib + Atezolizumab in Subjects with Metastatic Castration-Resistant Pros

  A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
  

  ---

• Phase 3 Study of Niraparib in Prostate Cancer

  A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer
  

  ---

Renal

• Phase 3 Study of MK-6482 with Lenvatinib for Metastatic Renal Cell Cancer Patients

  An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti-PD-1/L1 Combination Regimen
  

  ---

Solid Tumors

• Trial of Nab-Sirolimus for patients with malignant solid tumors with TSC1 or TSC2 alterations

  A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)
  

  ---

• A Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors

  A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors (NC318-01)
  

  ---

• Seribantumab in patients with NRG1+ locally advanced or metastatic solid tumors

  A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
  

  ---

• A Phase 2 study of Seribantumab in Patients with Solid Tumors

  A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
  

  ---

• A Phase 1b/2 study of XMT-1536 in solid tumors

  A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)
  

  ---